Allogeneic dendritic cell fusion vaccines

BruCells is developing allogeneic dendritic cell fusion vaccines as a therapeutic cancer immune therapy targeted at treating glioma or renal cell carcinoma (RCC). The active substance consists of hybrid cells resulting from the fusion of allogeneic dendritic cells (DC) with allogeneic glioma or RCC tumour cells. Therefore the fusion vaccine qualifies as a somatic cell therapy medicinal product, as defined in Part IV (Advanced therapy medicinal products) of annex I to Directive 2001/83/EC (1), as amended by Directive 2003/63/EC (2).

(1) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.

(2) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use.

created over 15 years ago (24 February 2010)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]